Investor Type | Firm |
Type of Fund | Venture Capital Fund |
Industries | BioTech • HealthTech (& Fitness) • Medical Devices (& Hospital Services) |
Stages | Seed, Startup, Early Stage |
Investing | United States • Canada • Israel • Europe |
Investment Range | $250,000 - $10,500,000 |
Assets Under Management | $145,000,000 |
MASA Life Science Ventures, LP, also known by the name Contour Venture Partners, is a venture capital fund specializing in seed, startup, and early stage investments. With their headquarters at 475 Park Avenue South, 6th Floor, New York, New York, the firm focuses its investment strategies within the BioTech, HealthTech (& Fitness), and Medical Devices (& Hospital Services) sectors. As a venture capital fund, they uphold an equity expertise and manage assets amounting to $145,000,000. They engage with companies for investments ranging from a minimum of $250,000 to a maximum of $10,500,000. Known as the most seasoned seed stage venture capital firm focused on the New York City technology ecosystem, Contour Venture Partners prides itself on partnering with passionate entrepreneurs and management teams to build businesses that aspire to transform their respective industries. Contour invests in companies that provide innovative software solutions into the enterprise SaaS, vertical B2B SaaS, and financial services sectors, with a particular emphasis on New York City. The firm has been the first institutional investor for many of its portfolio companies, committing capital to seed rounds and subsequent funding rounds, playing a critical role in guiding these companies from the early stages to significant growth and even to IPO in certain cases. They consider themselves not just an investor but a true business partner, actively contributing to various facets of business development, from strategic decision making to operational assistance, and financial structuring. The firm's portfolio showcases a combined annual revenue of $2.8 billion and includes over 105 companies, illustrating their substantial impact on the technology and life science sectors.